Deriphyllin

Reading File

Finding Sources

Reading File

Finding Sources

Here is a comprehensive overview of Deriphyllin, a combination bronchodilator widely used in South Asia (India, Bangladesh, etc.).

Deriphyllin

What Is It?

Deriphyllin is a fixed-dose combination of:

Component	Dose (per tablet/injection)
Etofylline (7-hydroxyethyltheophylline)	77 mg (tab) / 169.4 mg (inj)
Theophylline	23 mg (tab) / 50.6 mg (inj)

The ratio is approximately 77:23 (etofylline:theophylline). It is available as tablets, retard (sustained-release) tablets, syrup, and injectables (IV/IM).

Deriphyllin is a brand name popular in India. It belongs to the methylxanthine class of bronchodilators.

Mechanism of Action

Both components are methylxanthines and act via multiple complementary pathways:

1. Phosphodiesterase (PDE) Inhibition

Non-selective inhibition of PDE enzymes (especially PDE3, PDE4, PDE5) in airway smooth muscle
This raises intracellular cAMP and cGMP → smooth muscle relaxation → bronchodilation

2. Adenosine Receptor Antagonism

Blocks adenosine A1 and A2 receptors
Adenosine causes bronchoconstriction in asthmatic airways by releasing histamine and leukotrienes — blocking this effect provides relief
⚠️ Adenosine A1 antagonism is also responsible for cardiac arrhythmias and seizures at toxic levels

3. Anti-inflammatory Effects

Stimulates release of IL-10 (broad anti-inflammatory cytokine)
Inhibits NF-κB translocation → reduces expression of inflammatory genes
Promotes apoptosis of eosinophils and neutrophils → less chronic inflammation

4. Diaphragm Stimulation

Improves contractility of the respiratory muscles, which is useful in COPD with respiratory fatigue

Etofylline is included because it shares theophylline's bronchodilator properties but is considered slightly better tolerated (less CNS stimulation, less adenosine antagonism at equivalent doses).

Indications

Acute and chronic bronchial asthma
COPD (chronic obstructive pulmonary disease) — as add-on therapy
Acute bronchospasm (IV form used in hospital settings)
Cardiac asthma (with caution)
Cheyne-Stokes respiration (theophylline stimulates central respiratory drive)

Pharmacokinetics

Parameter	Detail
Absorption	Rapid oral absorption; food may delay but not reduce absorption
Distribution	Wide tissue distribution; crosses blood-brain barrier and placenta
Metabolism	Hepatic — primarily via CYP1A2
Elimination	Renal; half-life ~8–9 hours (variable)
Therapeutic range	5–15 mg/L (serum theophylline levels)

Adverse Effects

Adverse effects are concentration-dependent and occur more commonly when serum theophylline > 15 mg/L:

System	Effect
GI	Nausea, vomiting, abdominal discomfort, increased acid secretion (most common)
CNS	Headache, restlessness, insomnia, behavioral disturbances in children
CVS	Palpitations, tachycardia, cardiac arrhythmias (at high levels — PDE3 + A1 antagonism)
CNS (toxic)	Seizures (very high levels — central A1 receptor antagonism)
Renal	Diuresis

Drug Interactions

Theophylline levels are raised (toxicity risk) by:

CYP1A2 inhibitors: Ciprofloxacin, erythromycin, cimetidine, allopurinol, fluvoxamine, zileuton, zafirlukast
Conditions: CHF, liver disease, pneumonia, viral infections, old age, high-carbohydrate diet

Theophylline levels are lowered (reduced efficacy) by:

CYP1A2 inducers: Rifampicin, phenytoin, carbamazepine, smoking, high-protein diet

Clinical Use & Current Status

IV aminophylline/deriphyllin is less effective than nebulized β₂ agonists for acute asthma; it should be reserved for patients not responding to or intolerant of β-agonists
Oral theophylline-containing combinations remain affordable and widely used in developing countries where inhaled therapy may be cost-limiting
As an add-on to ICS in uncontrolled asthma, theophylline provides better symptom control than doubling ICS dose
Inhaled anticholinergics and β₂ agonists are preferred over theophylline in COPD; Deriphyllin is added in more severe/refractory disease

Therapeutic Drug Monitoring

Serum theophylline monitoring is mandatory with chronic use. Target: 5–10 mg/L (low-dose strategy largely avoids side effects while retaining clinical benefit).

Available Formulations (India)

Form	Strength
Tablet	Etofylline 77 mg + Theophylline 23 mg
Retard tablet	Etofylline 231 mg + Theophylline 69 mg (SR)
Injection	Etofylline 169.4 mg + Theophylline 50.6 mg/2 mL
Syrup	Etofylline 77 mg + Theophylline 23 mg/10 mL

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews: Pharmacology

This is a shared conversation. Sign in to Orris to start your own chat.